Imagine new medicines that effectively fight cancer, but may result in fewer side effects thanks to more accurate targeting of tumor cells. Today, PhRMA released a new video that highlights these promising new therapies called antibody drug conjugates, or ADCs.
Currently being investigated by several of our member companies, including Pfizer, these medicines may be more effective in targeting and destroying tumors when used in combination with current therapies, such as chemotherapy. ADCs represent a continuing shift in the cancer treatment landscape toward personalized medicines that more accurately attack specific targets fueling cancer cell growth while leaving more healthy cells unharmed.
“You can think of them as smart bombs, basically. Precision weapons against cancer,” says Pfizer’s senior vice president & group leader, oncology, Dr. Robert Abraham, in a testimonial during the video.
This is an exciting time in science, and ADCs are just one example of how biopharmaceutical companies are taking the lead in medical discovery that is helping patients live longer, healthier lives. Currently, more than 800 medicines and vaccines are in development to combat cancer – including ADCs, which may provide patients the same level of benefits of standard chemotherapy without some of the side effects that often accompany such treatments.
Andrew Powaleny is Senior Director of Public Affairs at PhRMA and leads the organizations scientific communications. Before joining PhRMA in 2015, he worked in public affairs for a small firm in Washington, DC and served as Deputy Press Secretary for the House Committee on Energy and Commerce. Andrew came to Washington, D.C. via Connecticut with a degree from Eastern Connecticut State University where he majored in public policy and government. Andrew is active as a runner and volunteer with the DC Front Runners; most recently serving on its Board of Directors for three years as co-race director. He is also a member of the NLGJA: The Association of LGBTQ Journalists and mentors students through his alumni association with The Fund for American Studies. Andrew is passionate about scientific innovation, especially for mental illness, and his heroes are the men and women of America’s biopharmaceutical research companies.